|
|
Article: Exact Sciences' Genomics-based Colorectal Cancer Technology Subject of $4.9 Million Grant to Mayo Clinic From National Cancer Institute.
- Article from:
- Business Wire
- Article date:
- June 25, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors and Health/Medical Writers
BIOWIRE2K
MAYNARD, Mass.--(BW HealthWire)--June 25, 2001
EXACT Sciences Corporation (NASDAQ: EXAS) announced today that its genomics-based colorectal cancer technology will be the subject of a study by Mayo Clinic for which Mayo Clinic received a $4.9MM grant from the National Cancer Institute of the National Institutes of Health. The study will involve 4,000 patients at average risk for developing colorectal cancer, and compare the results of EXACT Sciences' non-invasive, genomics-based screening technology with those of the fecal occult blood test, a common first-line colorectal cancer screening ...